Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Search

Page Path
HOME > Search
23 "Hwi Joong Yoon"
Filter
Filter
Article category
Keywords
More +
Publication year
More +
Authors
More +
Original Articles
Increased ERCC Expression Correlates with Improved Outcome of Patients Treated with Cisplatin as an Adjuvant Therapy for Curatively Resected Gastric Cancer
Sun Kyung Baek, Si-Young Kim, Jae Jin Lee, Yoon Wha Kim, Hwi Joong Yoon, Kyung Sam Cho
Cancer Res Treat. 2006;38(1):19-24.   Published online February 28, 2006
DOI: https://doi.org/10.4143/crt.2006.38.1.19
AbstractAbstract PDFPubReaderePub
Purpose

It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)-DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. We investigated whether the ERCC1 expression was associated with survival for gastric cancer patients in an adjuvant setting.

Materials and Methods

We retrospectively analyzed 44 patients who were diagnosed with stage II or higher disease after undergoing curative resection and they had also received cisplatin-based chemotherapy. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and this was divided into two groups according to the percentage of IHC staining of the tumor cell nuclei (negative: 10% or less, positive: more than 10%).

Results

Among the 44 patients (ERCC1-negative/ERCC1-positive group=16/28), 32 patients were male and their median age was 52 years. There was no difference for the baseline characteristics of the two groups. The median follow-up duration was 41 months. The median disease-free survival (DFS) and the overall survival (OS) for the ERCC1-positive group were significant higher than those of the ERCC1-negative group (DFS: 40.4 vs. 14.6 months, p=0.02, OS: undefined vs. 20.4 months, p=0.008).

Conclusion

The overall survival in gastric cancer patients who received cisplatin-based adjuvant chemotherapy after a curative resection is higher in those patients showing the overexpression of the ERCC1 gene. However, prospective studies using the ERCC1 gene expression as a prognostic marker for the DNA repair activity are needed.

Citations

Citations to this article as recorded by  
  • Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients
    Chunchao Zhu, Qin Yang, Jia Xu, Wenyi Zhao, Zizhen Zhang, Danhua Xu, Yeqian Zhang, Enhao Zhao, Gang Zhao
    Journal of Translational Medicine.2019;[Epub]     CrossRef
  • The design, analysis and application of mouse clinical trials in oncology drug development
    Sheng Guo, Xiaoqian Jiang, Binchen Mao, Qi-Xiang Li
    BMC Cancer.2019;[Epub]     CrossRef
  • Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer
    Yang-Kun Wang, Su-Nan Wang, Ying-Ying Li, Gong-Ping Wang, Tian Yun, Chao-Ya Zhu, Bin-Feng Yang, Cong-Yang Li, Bo Jiang, Mei-Ling Zhu
    Cancer Biomarkers.2018; 21(2): 439.     CrossRef
  • The Profile of Serum microRNAs Predicts Prognosis for Resected Gastric Cancer Patients Receiving Platinum-Based Chemotherapy
    Jianning Song, Jie Yin, Zhigang Bai, Jun Zhang, Hua Meng, Jun Cai, Wei Deng, Xuemei Ma, Zhongtao Zhang
    Digestive Diseases and Sciences.2017; 62(5): 1223.     CrossRef
  • Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population
    Qiang Xu, Zuofu Zhang, Weixue Sun, Baiqiang Hu
    Mammalian Genome.2017; 28(5-6): 227.     CrossRef
  • Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis
    PENG SONG, QIN YIN, MING LU, BO FU, BAOLIN WANG, QINGHONG ZHAO
    Experimental and Therapeutic Medicine.2015; 9(4): 1393.     CrossRef
  • Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis
    Anqi Yao, You Wang, Xiaohong Peng, Rong Ye, Qiaoli Wang, Yuexiao Qi, Fuxiang Zhou
    Journal of Cancer Research and Clinical Oncology.2014; 140(12): 2107.     CrossRef
  • Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer
    Yalei Zhang, Haihong Yang, Yuan Qiu, Qiuhua Deng, Jun Liu, Meiling Zhao, Ping He, Mingcong Mo, Xusen Zou, Jianxing He
    Medical Oncology.2014;[Epub]     CrossRef
  • The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis
    Kong-Kong Wei, Lei Jiang, Yao-Yao Wei, Yu-Feng Wang, Xuan-Kun Qian, Qiang Dai, Quan-Lin Guan
    Tumor Biology.2014; 35(9): 8721.     CrossRef
  • ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
    Sara De Dosso, Elena Zanellato, Martina Nucifora, Renzo Boldorini, Angelica Sonzogni, Roberto Biffi, Nicola Fazio, Eraldo Bucci, Ottavio Beretta, Stefano Crippa, Piercarlo Saletti, Milo Frattini
    Cancer Chemotherapy and Pharmacology.2013; 72(1): 159.     CrossRef
  • Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma
    Malcolm H. Squires, Sarah B. Fisher, Kevin E. Fisher, Sameer H. Patel, David A. Kooby, Bassel F. El‐Rayes, Charles A. Staley, Alton B. Farris, Shishir K. Maithel
    Cancer.2013; 119(17): 3242.     CrossRef
  • GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population
    Hui-Yan Li, Xin Ge, Guang-Ming Huang, Kai-Yu Li, Jing-Quan Zhao, Xi-Miao Yu, Wen-Si Bi, Yu-Lin Wang
    Asian Pacific Journal of Cancer Prevention.2012; 13(7): 3465.     CrossRef
  • Association of Four ERCC1 and ERCC2 SNPs with Survival of Bone Tumour Patients
    Ting Hao, Wei Feng, Jie Zhang, Yong-Jian Sun, Gang Wang
    Asian Pacific Journal of Cancer Prevention.2012; 13(8): 3821.     CrossRef
  • The Real Estate of Gastric Cancer Induction Therapy: Location Versus Intrinsic Molecular Architecture
    Roderich E. Schwarz, John C. Mansour
    Annals of Surgical Oncology.2012; 19(7): 2081.     CrossRef
  • Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy
    Ki Han Kim, Hyuk-Chan Kwon, Sung Yong Oh, Sung Hyun Kim, Suee Lee, Kyung A Kwon, Jin Seok Jang, Min Chan Kim, Su-Jin Kim, Hyo-Jin Kim
    Biomarkers.2011; 16(1): 74.     CrossRef
  • ERCC1: Impact in Multimodality Treatment of Upper Gastrointestinal Cancer
    Ralf Metzger, Elfriede Bollschweiler, Arnulf H Hölscher, Ute Warnecke-Eberz
    Future Oncology.2010; 6(11): 1735.     CrossRef
  • Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
    J-S Kim, M-A Kim, T M Kim, S-H Lee, D-W Kim, S-A Im, T-Y Kim, W H Kim, H-K Yang, D S Heo, Y-J Bang, K-U Lee, K-J Choe, N K Kim
    British Journal of Cancer.2009; 100(5): 732.     CrossRef
  • 12,950 View
  • 61 Download
  • 17 Crossref
Close layer
The Efficacy of a Modified Chronomodulated Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin in Advanced Colorectal Cancer (Preliminary Data)
Ji Young Park, Si-Young Kim, Jae Jin Lee, Hwi Joong Yoon, Kyung Sam Cho
Cancer Res Treat. 2004;36(3):199-204.   Published online June 30, 2004
DOI: https://doi.org/10.4143/crt.2004.36.3.199
AbstractAbstract PDFPubReaderePub
Purpose

To determine the efficacy and tolerability of a modified chronomodulated infusion of oxaliplatin, 5-fluorouracil (5-FU) and leucovorin in the treatment of advanced colorectal cancer.

Materials and Methods

Sixteen patients with relapsed or metastatic colorectal cancer were treated with an intravenous infusion of oxaliplatin 25 mg/m2, 5-FU 700 mg/m2 and leucovorin 20 mg/m2 on days 1 to 5. The infusion of oxaliplatin was chronomodulated with a peak delivery rate at 16:00 p.m., with 5-FU infused constantly overnight. Each course was repeated every 21 days.

Results

The response rate was 38.5% (95% confidence interval [CI], 13.9% to 68.4%) in the 13 measurable patients, including 1 complete response (7.7%) and 4 partial responses (30.8%). Five patients (38.5%) had a stable disease and 3 (23.0%) a progressive disease. Three patients without a measurable lesion had improved status. The median time to progression and overall survival were 29 weeks and 85 weeks, respectively. Grade 3 thrombocytopenia occurred in 2.5% (2 cycles) and grade 3 vomiting in 12.5% (2 patients). Anorexia, stomatitis, diarrhea, pruritus, alopecia and peripheral neuropathy were mild and tolerable.

Conclusion

The modified chronomodulated infusion of oxaliplatin, 5-FU and leucovorin is effective and tolerable, but the number of patients was too small. Further study will be needed to confirm the efficacy of this regimen with a larger population of patients.

Citations

Citations to this article as recorded by  
  • Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil and Low Dose Leucovorin in Patients with Advanced Colorectal Cancer
    Yoon Mi Shin, Hae Suk Han, Seong Woo Lim, Byung Chul Kim, Kyung Suck Cheoi, Young Ook Eum, Seung Taek Kim, Ki Hyeong Lee
    Cancer Research and Treatment.2005; 37(5): 284.     CrossRef
  • 9,518 View
  • 45 Download
  • 1 Crossref
Close layer
Randomized Phase III Trial of Cisplatin, Epirubicin, Leucovorin, 5-Fluorouracil (PELF) Combination versus 5-fluorouracil Alone as Adjuvant Chemotherapy in Curative Resected Stage III Gastric Cancer
Jae Jin Lee, Si-Young Kim, Im sik Shin, Kyung Sam Cho, Hoong-Zae Joo, Choong Yoon, Yoon Wha Kim, Hwi Joong Yoon
Cancer Res Treat. 2004;36(2):140-145.   Published online April 30, 2004
DOI: https://doi.org/10.4143/crt.2004.36.2.140
AbstractAbstract PDFPubReaderePub
Purpose

The combination of cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) administration, as adjuvant chemotherapy after curative resection for gastirc cancer, was compared with 5-fluorouracil (5-FU) administration alone. This paper reports the results of a prospective randomized comparison of the two regimens, PELF and 5-FU.

Methods

From August 1996 to July 1999, 54 patients were selected subsequent to being diagnosed with stage III cancer after a curative resection for gastric cancer. The patients were stratified according to stage IIIA/IIIB and subtotal/total gastrectomy, and then they were randomized into each treatment group, i.e. the PELF or 5-FU alone groups.

Results

54 assessable patients were enrolled in this study: 28 received PELF and 26 received 5-FU alone. 12 patients relapsed in each group and the median follow-up duration was 42 months (range: 10~77 months). The overall survival rate and disease-free survival rate (DFS) were not significantly different between two groups, (5-year survival of PELF vs. 5-FU: 57% vs. 64%, 5-year DFS: 54% vs. 51%). The PELF combination was more toxic in terms of anemia, anorexia, nausea and diarrhea than the 5-FU.

Conclusions

This study showed that the PELF combination, as an adjuvant therapy for gastric cancer after a curative resection, was a less effective treatment, and it had more toxic effects than the 5-FU.

Citations

Citations to this article as recorded by  
  • Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review
    Kotaro Sugawara, Yoshikuni Kawaguchi, Yasuyuki Seto, Jean-Nicolas Vauthey
    Surgical Oncology.2021; 38: 101599.     CrossRef
  • The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis
    Tom van den Ende, Emil ter Veer, Mélanie Machiels, Rosa M. A. Mali, Frank A. Abe Nijenhuis, Laura de Waal, Marety Laarman, Suzanne S. Gisbertz, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Cancers.2019; 11(1): 80.     CrossRef
  • Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
    Tom van den Ende, Emil ter Veer, Rosa M. A. Mali, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Cancers.2019; 11(4): 530.     CrossRef
  • COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
    Tom van den Ende, Frank A. Abe Nijenhuis, Héctor G. van den Boorn, Emil ter Veer, Maarten C. C. M. Hulshof, Suzanne S. Gisbertz, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis
    Zhaolun Cai, Yiqiong Yin, Yuan Yin, Chaoyong Shen, Jian Wang, Xiaonan Yin, Zhixin Chen, Ye Zhou, Bo Zhang
    Gastric Cancer.2018; 21(6): 1031.     CrossRef
  • Current challenges of metastatic breast cancer
    Bora Lim, Gabriel N. Hortobagyi
    Cancer and Metastasis Reviews.2016; 35(4): 495.     CrossRef
  • Management of Gastroesophageal Junction Tumors
    Matthew P. Fox, Victor van Berkel
    Surgical Clinics of North America.2012; 92(5): 1199.     CrossRef
  • 9,834 View
  • 61 Download
  • 7 Crossref
Close layer
Prognostic Effect of Vascular Endothelial Growth Factor and Angiogenesis in Gastric Carcinoma
Myoung Im Kim, Si Young Kim, Jae Jin Lee, Hwi Joong Yoon, Yoon Wha Kim, Kyung Sam Cho
Cancer Res Treat. 2003;35(3):218-223.   Published online June 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.3.218
AbstractAbstract PDF
PURPOSE
Many studies have shown that angiogenesis has an important role in the growth, progression, and metastasis of solid tumors. Recently, several angiogenic factors have been identified. Vascular endothelial growth factor (VEGF) is a well characterized inducer of angiogenesis. In this study, we investigated the prognostic significance of the expression of VEGF in patients with an advanced gastric carcinoma. MATERIALS AND METHODS: Specimens from 54 gastric adenocarcinoma patients were stained using a polyclonal antibody against VEGF. Correlations of the expression of VEGF, microvessel density, and various other clinicopathological factors were analysed. RESULTS: Seventeen (31.5%) and 37 cases (68.5%) were VEGF-negative and positive, respectively. There was significant correlation between the expression of VEGF and pathological differentiation. There were no significant correlations between the expression of VEGF, stage and recurrence of a gastric carcinoma. The microvessel density was significantly higher in the VEGF-positive than the VEGF-negative tumors. Survivals of the VEGF-negative patients were significantly prolonged compared to those of the VEGF-positive patients. CONCLUSION: The results of this study show that the expression of VEGF may be a useful prognostic factor for patients with a gastric adenocarcinoma.

Citations

Citations to this article as recorded by  
  • RETRACTED ARTICLE: KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis
    Changhwan Yoon, Jun Lu, Yukyung Jun, Yun-Suhk Suh, Bang-Jin Kim, Jacob E. Till, Jong Hyun Kim, Sara H. Keshavjee, Sandra Ryeom, Sam S. Yoon
    BMC Cancer.2023;[Epub]     CrossRef
  • Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer
    Jong Gwang Kim, Yee Soo Chae, Sang Kyun Sohn, Yoon Young Cho, Joon Ho Moon, Jae Yong Park, Seoung Woo Jeon, In Taek Lee, Gyu Seog Choi, Soo-Han Jun
    Clinical Cancer Research.2008; 14(1): 62.     CrossRef
  • 3,938 View
  • 19 Download
  • 2 Crossref
Close layer
Pilot Study of Heptaplatin, UFT-E and Leucovorin in Advanced Gastric Carcinoma
Sang Cheul Oh, So Young Yoon, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho, Jun Suk Kim
Cancer Res Treat. 2003;35(2):117-122.   Published online April 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.2.117
AbstractAbstract PDF
PURPOSE
Heptaplatin (SKI-2053R, Sunpla ), a new platinum analogue which has a better toxicity profile than cisplatin, has been used with 5-fluorouracil (5-FU) continuous infusion for the treatment of advanced gastric carcinoma. However, continuous 5-FU infusion had a inconvenience to administration. The aim of this study was to evaluate the efficacy and toxicity of heptaplatin, UFT-E and leucovorin combination chemotherapy in advanced gastric cancer.
MATERIALS AND METHODS
A total of 22 patients was enrolled in this study at Kyung Hee University and Korea University from September 1999 to May 2001. Heptaplatin 400 mg/m2 was given as intravenous infusion for 1 hour at day 1. Oral UFT-E 360 mg/m2 and leucovorin 45 mg/day were administered for 21 consecutive days followed by a 7-day drug free interval. This schedule was repeated every 4 weeks. RESULTS: The 22 enrolled patients received 81 courses of chemotherapy and the median number of course per patient was three with a range of one to six. Five of 21 patients achieved partial responses (23.8%; 95% confidence interval, 5.6% to 42%) without complete response. Out of the 5 responding patients, three had unresectable perigastric lymph-nodes, one patient had a ovarian metastasis, and one patient had a peritoneal metastasis respectively. Main toxicities were neutropenia and nausea/vomiting. Grade 3 and 4 neutropenia were observed in 4 patients (18%) and grade 3 nausea/vomiting were observed in 5 patients (22.7%). The median time to progression was 4 months (range, 0.5 to 13 months), and median survival duration was 7.5 months (range, 2.0 to 14 months). Median response duration was 5.0 months (range, 1.5 to 10 months). CONCLUSION: A combination chemotherapy of heptaplatin, UFT-E and leucovorin has a comparable efficacy with those of previously reported heptaplatin and intravenous regimen of 5-FU and controllable toxicity in advanced gastric carcinoma. Further study with large patient population is warranted to determine the usefulness of this regimen.

Citations

Citations to this article as recorded by  
  • Platinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclusters
    Xi Hu, Fangyuan Li, Nabila Noor, Daishun Ling
    Science Bulletin.2017; 62(8): 589.     CrossRef
  • The status of platinum anticancer drugs in the clinic and in clinical trials
    Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
    Dalton Transactions.2010; 39(35): 8113.     CrossRef
  • A Phase II Trial of Haptaplatin/5-FU and Leucovorin for Advanced Stomach Cancer
    Won Sup Lee, Gyeong-Won Lee, Hwal Woong Kim, Ok-Jae Lee, Young-Joon Lee, Gyung Hyuck Ko, Jong-Seok Lee, Joung Soon Jang, Woo Song Ha
    Cancer Research and Treatment.2005; 37(4): 208.     CrossRef
  • Combination Chemotherapy of Heptaplatin, Paclitaxel and 5-Fluorouracil in Patients with Advanced Gastric Cancer: a Pilot Study
    Myung-Ju Ahn, Ho-Suck Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Oh Young Lee, Ho-Soon Choi, Sung-Joon Kwon
    Cancer Research and Treatment.2004; 36(3): 182.     CrossRef
  • 4,621 View
  • 23 Download
  • 4 Crossref
Close layer
Randomized Controlled Open Labelled, Phase III Trials, Comparing the Efficacy between Fentas(R) and Durogesic(R) Patches in Controlling Cancer Pain: Multicenter Trial
Myung Ju Ahn, Tae June Jung, Jung Hye Choi, Mi Ran Oh, Hwi Joong Yoon, Jun Suk Kim, Chul Won Choi, Kyung Wook Hur, Dae Sik Hong, Hee Sook Park, Sung Kyu Park, Jung Ae Lee, Young Suk Park, Hyonggi Jung
Cancer Res Treat. 2002;34(3):165-169.   Published online June 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.3.165
AbstractAbstract PDF
PURPOSE
Fentanyl is a synthetic opioid and transdermal therapeutic system (TTS), designed to release the drug into the skin at a constant rate, ranging from 25 to 100 microgram/hr, for up to 3 days. For the control of chronic cancer pain, Durogesic(R) patches (Janssen Co., USA) are now widely used. Recently, the Hana Company in Korea developed a new fentanyl patch, Fentas(R) using a different method. To compare the efficacy, and safety, of the fentanyl patch manufactured in Korea (Hana Pharm. Co. Ltd), with the Durogesic(R) patch, in controlling cancer pain, we performed randomized controlled, open labelled, phase III studies. MATERIALS AND METGODS: From January 2000 to April 2001, 85 patients were enrolled, 69 of whom (42 in D arm and 43 in F arm) completed the study, and were therefore assessable for per protocol (PP) analyses.
RESULTS
There were no significant differences between the two groups in baseline characteristics, with the exception of age. The primary end point was to show the therapeutic equivalence of the two patches. In these clinical trials, the confidence interval of difference, between the test drug (Fentas(R)) and the control (Durogesic(R)), was 0.027~ +0.124 by intention to treat (ITT) analysis. Even if the upper confidence interval exceeds + 0.1, the test drug is not superior to the control drug, because the confidence interval includes 0. However, by PP analysis, the confidence interval lies exactly within +/- 0.1. Therefore, we could conclude the two patches are therapeutically equivalent. The second endpoint was the difference of visual analog scale (VAS) between the baseline and the average of three measurements after treatment. The difference in VAS was 50.44+/-10.28 for the F arm, and 44.69+/-11.00 for the D arm. By PP analysis the test drug was superior to the control (p=0.028). The rescue morphine amount was 81.21+/-124.76 for F arm and 66.19+/-115.9 for D arm, and there was no significant difference between the two groups (p=0.6063). The most common adverse effects of both fentanyl patches were nausea or vomiting (55.3%), somnolence (50.0%), constipation (39.5%), gastrointestinal discomfort (57.9%) and headaches (25.0%). In general there was no significant difference in side effects or laboratory data between the two groups.
CONCLUSION
These findings suggest that Fentas(R) patches, administered every 3 days, are effective, safe, and well tolerated for the treatment of most patients with cancer pain and is as effective or better than Durogesic(R).
  • 4,533 View
  • 33 Download
Close layer
Case Report
A Case of Intracardiac Lymphoma as a Presentation of Non Hodgkin's Lymphoma
Gun Lee, Kyung Sam Cho, Suk Chon, Young Hee Joung, Cheon Woong Choi, Si Young Kim, Hwi Joong Yoon
Cancer Res Treat. 2001;33(5):438-441.   Published online October 31, 2001
DOI: https://doi.org/10.4143/crt.2001.33.5.438
AbstractAbstract PDF
Lymphomatous involvement of the heart is extremely rare at initial diagnosis and presentation of malignant lymphoma. Worldwide, only a few cases have been diagnosed and treated during life and only four cases were diagnosed before death in Korea. We report a case of non-Hodgkin's lymphoma with two right atrial masses detected by chest computed tomography and transesophageal echocardiography. The patient was an 80 year- old man and the presenting symptoms included generalized weakness, weight loss, constipation and low abdominal pain. For diagnosis, the mass of the perinephric area was biopsied under ultrasonographic guidance, and pathologically it was determined to be malignant lymphoma, diffuse large B cell type. The patient was treated with continuous low dose cyclophosphamide and prednisolone vice standard chemotherapy because of advanced age and renal dysfunction. After 2 months of treatment the masses in the atrium and the intraabdominal masses disappeared.
  • 3,885 View
  • 26 Download
Close layer
Original Articles
Analysis of 103 Patients with Unknown Primary Carcinoma: Retrospective Study
Jae Jin Lee, Si Young Kim, Kyung Sam Cho, Juhie Lee, Hwi Joong Yoon
J Korean Cancer Assoc. 2001;33(1):1-8.
AbstractAbstract PDF
PURPOSE
Unknown primary carcinoma takes up approximately 0.5-10% of the oncology patients evaluated, and the patients have poor survival of between 3 to 11 months. Despite the short survival, certain clinically defined subsets of patients were reported to have a better prognosis. Thus, the objective of this study was to identify prognostic factors.
MATERIALS AND METHODS
The present study was con ducted with 103 patients who were referred from January 1988 to July 1999. The primary end point was survival. The survival curves were estimated using the Kaplan-Meier method and compared using the Log-rank test and Cox's proportional hazards regression analysis.
RESULTS
Most patients had histologic evidence of ade nocarcinoma or squamous cell carcinoma. Univariate and multivariate analyses identified good prognostic factors including performance status (grade 0-2), female and adenocarcinoma with more than moderate level of differentiation. The responders of chemotherapy in squamous cell carcinoma and lung, breast, ovary -estimated- cancer showed good survival rates.
CONCLUSION
Unknown primary carcinoma tended to show a poor prognosis. However, when treatment modality of unknown primary carcinoma is to be determined through the prognostic factors, the patients quality of life can be improved through reducing the treatment side effects and economic burden on the patients.
  • 3,006 View
  • 34 Download
Close layer
Expression of p53, bcl-2 Protein in Small Cell Lung Cancer (SCLC) Cell Lines in Relation to Sensitivity to Chemotherapy
In Sook Woo, Myung Jae Park, Young Seok Park, Sung Won Jung, Mi Ae Yeo, Soo Hyun Park, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho, Jae Kyung Park, Young Il Kim
J Korean Cancer Assoc. 2000;32(5):904-910.
AbstractAbstract PDF
PURPOSE
Sensitivity of tumor cells to chemotherapeutic regimen may be accentuated by their abnormal expression of oncogene. p53 is required for the efficient activation of apoptosis following irradiation or treatment with chemotherapeutic agents. The aim of this study was to evaluate the relationship between chemosensitivity and apoptosis related proteins such as p53, bcl-2 in small cell lung cancer cell lines. MATERIAL AND METHODS: Six human small cell lung cancer cell lines, NCI-H69, NCI-H128, NCI-H1436, NCI-H1092, derived from untreated and treated patients were tested for chemo sensitivity and the expression of the p53, bcl-2 genes were examined in each cell lines with western blot analysis. We used 4 drugs including adriamycin, cisplatin, vincristine and VP-16.
RESULTS
NCI-H128 was the most sensitive cell line to four drugs. NCI-H82 and NCI-H1092 were highly resistant to VP-16, adriamycin and vincristine and determination of an IC50 was not possible. In western blot analysis, NCI-H128 alone was strong positive to p53 monoclonal antibody and the rest of cell lines were negative. All but NCI-H128 were positive to bcl-2 monoclonal antibody. NCI-H128 which was strong positive to p53 and negative to bcl-2. NCI-H1092 was strong positive to bcl-2 and negative to p53 monoclonal antibody.
CONCLUSION
We were not able to explain the expression of p53 in small cell lung cancer cell lines in relation to senitivity to anti-cancer chemotherapeutic agents. But the expression of bcl-2 in small cell lung cancer cell lines was correlated with the chemosensitivity well.
  • 4,054 View
  • 71 Download
Close layer
Combination Chemotherapy with VP - 16 , Ifosfamide , and Cisplatin ( VIP ) in the Advanced Non - Small Cell Lung Cancer
Yong Seon Cho, Si Young Kim, Jeong Hee Kim, Hwi Joong Yoon, Kyung Sam Cho
J Korean Cancer Assoc. 2000;32(1):86-92.
AbstractAbstract PDF
PURPOSE
We conducted a phase II study in previously untreated patients with unresectable stage IIIB or IV non-small cell lung cancer to evaluate the response rate and toxicity of the combination chemotherapy regimen of etoposide, ifosfamide and cisplatin. MATERIALS AND METHODS: From September 1993 to December 1996, twenty patients with advanced non-small cell lung cancer (stage IIIB 5 and IV 15) (squamous cell 8, adeno- carcinoma 12), were enrolled in this study. There were 13 (65%) males and 7 (35%) females, and median age of patients were 56 years (range: 34~66). Eighteen patients had performance status (ECOG) 0~1, two patients had performance status 2. Treatment was consisted of cisplatin (20 mg/m2 i.v., day 1~4), VP-16 (etoposide) (75 mg/m2 i.v., day 1~4), ifosfamide (1000 mg/m2 i.v., day 1~4) with mesna. This treatment was repeated every four weeks.
RESULTS
The overall response rate was 25%. Complete response rate was 5% (1/20) and partial response rate was 20% (4/20). The median cycle of response was 4 (2~6) cycles. The median overall survival time was 28 weeks (9~98 weeks). The median time to progression was 10 weeks (3~50 weeks). Toxicities were evaluated by WHO criteria. Toxicity > GradeIII included: leukopenia 1.6%, thrombocytopenia 3.2%, nausea and vomiting 15%, alopecia 30%, stomatitis 10%. These toxicities were tolerable and reversible.
CONCLUSION
VIP regimen was not superior to previous regimens for advanced non-small all lung cancer, and the toxicities were tolerable.
  • 2,829 View
  • 14 Download
Close layer
Modulation of Telomerase Activity by p53 Gene in KATO - III Gastric Carcinoma Cell Line
Si Young Kim, Kyung Sam Cho, Jae Kyung Park, Young II Kim, Hwi Joong Yoon
J Korean Cancer Assoc. 1999;31(6):1112-1119.
AbstractAbstract PDF
PURPOSE
Alteration of p53 and telomerase activity may be responsible for gastric carcino- genesis. In this study, we tried to observe modulation of telomerase activity by wild type p53 in gastric cancer cell lines.
MATERIALS AND METHODS
We used five gastric cancer cell lines (KATO-III, AGS, SNU-1, SNU-5, SNU-16). In order to find p53 mutation, we used western blot and PCR-SSCP. The TRAP-eze kit which supplied by Oncor (Gaithersburg, MD) was used to detect telomerase activity of the five gastric carcinoma cell lines. The wild type p53 gene was transfected by electroporation method.
RESULTS
The expression of p53 protein was increased in four gastric carcinoma cell lines and one cell line (KATO-III) did not express. We found p53 point mutation in exon 5 and 8, and the p53 gene was deleted in KATO-III. The telomerase activity were observed in all five gastric carcinoma cell lines and there were no difference in telomere repeat length among five cell lines. After transfection with wild type p53, we could not find the change of telomerase activity in KATO-III.
CONCLUSION
Although activation of telomerase activity and mutation of p53 gene may be needed in gastric carcinogenesis, the telomerase activity was not affected by restoration of p53 function in gastric carcinoma cell lines.
  • 3,037 View
  • 75 Download
Close layer
Granisetron in the Prevention of Nausea and Vomiting in Patients Receiving Platinum - Containing Chemotherapy
Woo Shik Kim, Si Young Kim, Kyung Sam Cho, Jeong Hee Kim, Hwi Joong Yoon
J Korean Cancer Assoc. 1998;30(6):1249-1258.
AbstractAbstract PDF
PURPOSE
In gastric cancer, metastasis to the paraaortic lymph nodes had been regarded as an incurable factor, but many cases of long term survival have been reported with dissection of metastatic paraaortic nodes. And several reports suggested survival benefit with paraaortic lymph node dissection (D4) in advanced gastric cancer. In patients with advanced gastric cancer who underwent paraaortic lymph node dissection we tried to evaluate the factors predisposing metastasis in these nodes and survival data.
MATERIALS AND METHODS
The authors analyzed retrospectively pathological features of 95 patients who underwent paraacntic lymph node dissection for advanced gastric cancer at Kangnam General Hospital Public Corporation Bom May 1991 to Feb. 1998. And we also analysed survival results of 72 cases among them. We excluded 18 cases of distant metastasis (3 liver metastasis, 15 peritoneal seeding), 2 operative mortalities, 1 other disease mortality, and 2 unlmown causes of death in survival analysis.
RESULTS
The frequencies of paraaortic lymph node metastasis were 0.0% (0 of 32 cases) in T2, 19.2% (10 of 52 cases) in T3, 18.2% (2 of 11 cases) in T4. And those of paraaortic lymph node metastasis were 5.8% (3 of 52 cases) in antrum, 14.3% (3 fo 21 cases) in body, 20.0% (3 of 15 cases) in cardia, and 42.9% (3 of 7 cases) in whole area. The five-year survival rates (5 YSRs) in relation to the paraaortic lymph node (No16) status was 0.096 in No16+, and 57.8Po in Nol6 with D4 of advanced gastric cancer. The 5 YSRs were 78.1%, 40.8% and 0% in T2, T3 and T4, respectively and 93.8%, 64.2%, 24.2% and 0.0% in n0, nl, n2 and n.3, respectively and 88.9%, 80.5%, 57.9% and 0.0% (47.6%) and 0.0% in stage IB, II, IIIA, IIIB and IV, respectively.
CONCLUSION
The depth of gastric wall invasion and the location of primary tumor were significant predisposing factors to para-aortic lymph node metastasis in multivariate analysis (p<0.05). Survival of No16 metastasis was very poor. And three factors of T stage, n stage, and Bonmann type were also prognostically significant in terms of five year survival in cases of D4 of advanced gastric cancer in multivariate analysis (p < 0.05).
  • 2,790 View
  • 14 Download
Close layer
Cispatin , Etoposide , Leucovorin and 5-Fluorouracil ( PELF ) Combination Chemotherapy for Advanced Gastric cancer: Interim Report
Il Rang Park, Si Young Kim, Jeong Hee Kim, Hwi Joong Yoon, Kyung Sam Cho
J Korean Cancer Assoc. 1998;30(5):907-913.
AbstractAbstract PDF
PURPOSE
In attempt to provide a feasible chemotherapeutic regimen for advanced gastric cancer patients, the combination of cisplatin, epirubicin, leucovorin and fluorouracil (PELF) has been developed. A trial was performed to confirm the clinical activity, in terms of response rate and toxicity and duration of survival, of the PELF combination chemotherapy.
MATERIALS AND METHODS
From April 1995 to July 1997, patients with measurable unresectable and/or metastatic gastric cancer received PELF combination chemotherapy. The regimen consisted of cisplatin 40 mg/m2 IV on days 1 and 5; epirubicin 30 mg/m2 IV on days 1 and 5; 5-fluorouracil 300 mg/m2 and leucovorin 20 mg/m2 IV on days 1 through 4. The cycle was repeated every 3 weeks.
RESULT
Among 21 evaluable patients, 1 patient achieved complete response (5.3%) and 8 patients, partial response (42.1%). The median survival of overall patients was 36 weeks, the median time to progression of 21 evaluable patients was 27 weeks. There was severe myelosuppression; leucopenia 73.1%, WHO grade 3~4 11.5% of cycles. Non-hematologic toxicities were also severe nausea or vomiting in 100% of patients, grade 3~4 13.0% of patients, alopecia in 91.3% of patients, grade 3~4 52.2% of patients.
CONCLUSION
This study showed that the PELF combination is effective in overall response rates. However, it is not recommended for routine clinical use because of its toxicities. Further phase III study will be warranted.
  • 3,240 View
  • 17 Download
Close layer
Phase II Study of Ifosfamide, Epirubicin and Cisplatin(IEP) in Patients with Small Cell Lung Cancer
Hwi Joong Yoon, Hyun Joo Park, Si Young Kim, Kyung Sam Cho, Jung Hee Kim, Sung Eon Hong
J Korean Cancer Assoc. 1998;30(4):728-736.
AbstractAbstract PDF
PURPOSE
Although it is well recognized that SCLC is a chemo and radiosensitive tumor, only fraction of treated patients have a complete remission, fewer still have durable remissions. This study was performed to evaluate the clinical effects of IEP chemotherapy in patients with SCLC.
MATERIALS AND METHODS
Patients with histologically proven SCLC who has measurable disease and previously untreated, were eligible. Treatment consisted of ifosfamide 1000 mg/m2 iv infusion for 1 hour on days 1~5 with mesna uroprotection; epirubicin 60 mg/m2 iv on day 1; and cisplatin 20 mg/m2 iv infusion on days 1~5 with hydration; repeated treatment every 4 weeks RESULTS: Twenty four patients(20 males, 4 females) were eligible for response to IEP chemotherapy. The two patients were excluded because one died before evaluating response to chemotherapy and the other had brain metastasis. The median age was 61(range 34-74). Fifteen patients had a limited disease(LD), nine patients had a extensive disease(ED). The overall response rate was 86.4%(CR 36.4%, PR 50%). In LD, response rate was 86.7%(CR 46.7%) and in ED, response rate was 85.7%(CR 14.3%). The median overall survival time was 43.5 weeks. The median survival time of LD and ED was 46.5 weeks and 43.5 weeks respectively. The median time to progression was 20 weeks in responders. The toxicity was moderate. One toxic death was observed. Grade 1 or 2 non-hematologic toxicities consisted of alopecia, nausea and vomiting in all cases, peripheral neuropathy in 3, hematuria in 2, mucositis in 11, and fever/infection in 6. Hematologic toxic effects included leukopenia(> or =grade.3, 16.5%), anemia(> or =grade 3, 1%), and thrombocytopenia(> or =grade 3, 6.8%).
CONCLUSIONS
These results suggest that IEP chemotherapy may be useful as a treatment strategy in small cell lung cancer, but its efficacy is equivalent. The phase III study should be needed.
  • 3,076 View
  • 15 Download
Close layer
Efficacy of ondansetron is cisplatin-induced nausea and vomiting
Keum Jung Kim, Jung Baik Kim, Kwang Mi Kim, Jung Sook Park, Soo Hee Park, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho
J Korean Cancer Assoc. 1993;25(6):975-981.
AbstractAbstract PDF
No abstract available.
  • 2,514 View
  • 15 Download
Close layer
A case of primary mediastinal germ cell tumor associated with Klinefelter's syndrome
Keum Jung Kim, Wan Kyoo Uh, Si Young Kim, Hwi Joong Yoon, Kyung Sam Jo, Jae Hoon Park, Moon Ho Yang
J Korean Cancer Assoc. 1993;25(1):116-121.
AbstractAbstract PDF
No abstract available.
  • 2,977 View
  • 15 Download
Close layer
Etoposide, adriamycin, cisplatin(EAP) combination chemotherapy for advanced gastric cancer
Joon Sik Kim, Jeong Hee Kim, Own Gyu Uh, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho
J Korean Cancer Assoc. 1992;24(4):562-569.
AbstractAbstract PDF
No abstract available.
  • 2,356 View
  • 15 Download
Close layer
Cytotoxicities and Proliferation Responses in Lymphokine Activated Killer ( LAK ) Cells and Oxydizing Mitogen Activated Killer ( OMAK ) Cells
Hwi Joong Yoon, Kyung Sam Cho, Mun Ho Lee
J Korean Cancer Assoc. 1988;20(1):24-35.
AbstractAbstract PDF
LAK (lymphokine acitivated killer) cells, generated by incubation of lymphocytes with interleukin 2 (IL2), have cytotoxicity against fresh tumor cells, and adoptive immunotherapy of cancer with LAK is on clinical trial. OMAK (oxydiiing mitogen activated killer) cells are generated by incubation of oxydizing mitogen treated lymphocytes with IL2. This study was designed to compare the cytotox- icities and the proliferation responses of LAK and OMAK at various human AB serum (HABS) concentrations and durations of culture. Peripheral blood mononuclear cells, treated (OMAK) or untreated (LAK) with periodate, were incubated in RPM11640 with 10% IL2 and various concentrations of HABS. Proliferation responses were measured by H-thmidine uptake and cytotoxicites against K562 and RC29 (NK resistant) were measured by 4-hour Cr release method. OMAK showed higher prolfieration response and cytotoxicity against K562 and RC29 than LAK at 2nd day of culture with 5% HABS. Proliferation responses of LAK and OMAK increased in HABS added culture but cytotoxicities did not. Rather, cytotoxicities were hihger in LAK and OMAK cultured without HABS. Proliferation responses were not apparent at 1st day of culture. Peak responses were at 7th day in LAK and at 4th day in OMAK. Cytotoxicities against K562 were apparent at 1st day of culture in LAK and OMAK, and peaked at 4th day in LAK and at 3rd day in OMAK, but increment of cytotoxicities were only slight. Cytotoxicities against RC29 appeared at 2nd day in LAK and at 1st day in OMAK. LAK showed peak cytotoxicity from 3rd day to 7th day, but OMAK showed peak cytotoxicity at 3rd day and decreased afterwards. OMAK may have more advantages than LAK because of its higher and earlier-generated cytotoxicity.
  • 2,240 View
  • 13 Download
Close layer
Antigen Receptor Gene Rearrangement Patterans of Acute Lymphoblastic Leukemia - Preliminary study of detection of residual leukemic cells using polymerase chain r
Kyung Sam Cho, Young Il Kim, Seon Hee Kim, Si Young Kim, Hwi Joong Yoon
J Korean Cancer Assoc. 1994;26(4):591-599.
AbstractAbstract PDF
1) Background: Polymerase chain reaction (PCR) is a highly sensitive method to detect minimal residual disease (MRD). Although leukemia-specific translocations are detected only in minority of patients with acute lymphoblastic leukemia (ALL), several investigators developed methods to detect MRD by PCR, based on preferential usage of specific genetic elements, the limited number of VB and JB elements of T cell receptor (TCR) delta gene, and assembled V regions of immunoglobulin (Ig) gene containing re1atively conserved base sequences. 2) Methods: We evaluated antigen receptor gene rearrangement patterns of leukemic cells from ALL patients by southern blot technique, as a baseline study for the detection of MRD using PCR. 3) Results: Rearrangements of Ig heavy chain, TCR beta, gamma and delta chain gene were found in 68%, 68%, 64%, 9B% of patients respectively. So thern analysis of HindIII digests with JBS16 probe showed Vδ[Jδ] rearrangement in only 4 cases. 4) Conclusion: Heavy chain gene rearrangement is more suitable target for the application of PCR than TCR delta gene rearrangements for detection of MRD in ALL.
  • 2,185 View
  • 15 Download
Close layer
5-Fluorouracil and Cisplatin ( FP ) Combination Chemotherapy in Advanced Gastric Cancer
Keum Jung Kim, Jeong Hee Kim, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho
J Korean Cancer Assoc. 1995;27(3):383-389.
AbstractAbstract PDF
Thirty-one patients with advanced gastric cancer were entered into the trial between May 1988 to June l993. The patients recieved 5-fluorouracil 1,000 mg/m by l2-hour continuous infusions for 5 consecutive days, cisplatin 100 mg/m IV on day 1 and repeated every three weeks. The results were as following: 1) Among the 31 treated patients, 27 patients had measurable disease and were evaluable for response. The overall response rate was 18.5%. The median duration of response was 6 months. 2) The estimated median survival time was 7.5 months for all 31 patients. The median survival was 8.6 months in responder, and 6.4 months in non-responder. There was no significar.t difference between the two group. 3) Nausea and vomiting of WHO grades 2 and 3 were observed in 48.7%. Alopecia was observed in all patients, but most of patients were WHO grade l or 2. WHO grades 1 and 2 neurotoxicities and diarrhea occurred in 22.6%, 7.8% of patients. WHO grades 2 and 3 neutrope- nia were observed in 2.6% of patients and WHO grade 1 thrombocytopenia was observed in 9.6 of patients, but there were no toxic deaths and no bleeding complications from thrombocytopenia. In conclusion, although this PP regimen showed similar toxicity profiles than the other regimen, response rate and survival benefit were not observed.
  • 3,854 View
  • 33 Download
Close layer
A Clinical Study on Multiple Myelom
Jin Woo Jung, Jeong Hee Kim, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho
J Korean Cancer Assoc. 1995;27(5):869-879.
AbstractAbstract PDF
Clinical findings and results were analysed in 56 cases diagnosed as multiple myeloma between October 1981 and June l994 at Kyung Hee University Hospital. The resuts were as followings: 1) The incidence reached a peak during 7th decade and male to female ratio was 1.2:l. 2) The chief complaints at initial presentation were bone pain(50%), pathologic fracture (14%) and anemia(14%), 3) Hematologic findings showed anemia in 77%, leukopenia in 25% and thrombocytopenia in 23%. ESR was elevated in 91% of patients. Hypercalcemia was noted in l3% and renal failure in 29%. 4) X-ray findings showed pathologic fracture in 39%, osteolytic lesion in 70% and osteo-porosis in 32% but normal finding was found in 5% of patients. 5) Clinical stage was stage I in 8%, stage II in 19% and stage III in 73% of patients. Fifteen of sixteen patients with renal insufficiency were in stage III. 6) Serum protein electrophoresis showed a M-peak in 89%. Mean M-protein concentration was 4.55 g/dl. M-protein was IgG in 57%, IgA in 24%, IgD in 2% and light chain only in 17% . Kappa to lambda ratio was 1.4: l. 7) Varisnt forms of multiple myeloma were 2 cases of nonsecretory myeloma, 1 case of solitary plasmacytoma and 1 case of plasma cell leukemia. 8) Response rate to primary chemotherapy was 37% for MP regimen and 60% for M2 regimen. There was statistically significant survival difference between responders and non-responders(p<0.01). The overall median survival of patients was 76 weeks.
  • 2,740 View
  • 12 Download
Close layer
Neoadjuvant Chemotherapy with 5-Fluorouracil and Cisplatin for Locally Advanced Head and Neck Cancer
Ji Hoon Park, Hwan Suk Choi, Jeong Hee Kim, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho, Seong Eon Hong, Dong Mok Ryu, Hoe Young Ahn
J Korean Cancer Assoc. 1995;27(6):990-1002.
AbstractAbstract PDF
Background
The prognosis for patients with locally advanced head and neck cancer remains poor. In recent years, attempts at improving the poor survival rates have frquently focused on the initial use of chemotherapy followed by subsequent standard local therapy with surgery and radiation. Methods: Twenty-seven patients with previously untreated, locally advanced (stage III or IV) head and neck cancer were treated with 2 or 3 cycles of combination chemotherapy consisting of 5-fluorouracil infusion and cisplatin followed by operation or radiotherapy between January,1988 and March,1994. Results: 1) After the neoadjuvant FP chemotherapy, sixteen of 27 patients(59.2%) demonstrated an objective response, with one(3.7%) achieving a complete clinical response(CR) and fifteen(55.5%) a partial response(PR). After the definitive local therapy(DLT:operation or radiation therapy), 12(44.4%) patients had a CR and 12(44.4%) achieved PR, respectively with 88.8% overall response rates. 2) Twelve patients received operation and 15 patients received radiotherapy after the neoadjuvant chemotherapy. Among 12 patients who received operation, seven(58%) patients achieved curative resection with surgery and five(33%) patients a complete remission, seven patients(46.7%) a partial remission with radiotherapy. 3) The overall median survival of total 27 patients was 31 months. The median survival of the responders (median:54 months) to FP chemotherapy was not significantly prolonged compared with nonresponders(median:23 months). 4) Time to disease progression of the responders to definite local therapy was 19 months. 5) Leukopenia and thrombocytopenia were observed in 48%(grade I-III) and l0%(grade I- II) respectively. Nausea and vomiting were observed in all patients, but easily controlled. Alopecia, diarrhea, stomatitis and nephrotoxicity were observed infrequently. There were no treatment related fatalities. Conclusion: Neoadjuvant FP chemotherapy in patients with locally advanced head and neck cancer was tolerable, but did not improve the response rate and overall survival compared with previous other reports. The phase III randomized controlled prospective studies are warranted for the verification of this study
  • 3,138 View
  • 17 Download
Close layer
A Case of Relapse in Central Nervous System during the Chemotherapy of Testicular Lymphoma Stage 1
Wook Sun Choi, Si Young Kim, Jeong Hee Kim, Hwi Joong Yoon, Kyung Sam Cho
J Korean Cancer Assoc. 1996;28(6):1133-1139.
AbstractAbstract PDF
Primary testicular non-Hodgkin's Lymphoma is very rare. It may be the systemic manifestation of nodular lymphoma. The most common symptom of primary testicular lymphoma is the painless enlargement of testis. It frequently involves Waldeyer's ring, skin and central nervous system. The combination chemotherapy and CNS prophlylaxis may be needed in the treatment of early stage primary testicular non-Hodgkin's lymphoma. We are reporting a case of primary testicular non-Hodgkin's 1ymphoma stage I, which relapsed in central nervous system during combination chemotherapy.
  • 2,286 View
  • 13 Download
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP